m3taversal
a756745c18
- What: Converted 132 broken wiki links to plain text across 41 health domain files. Added Vida to the Active Agents table in CLAUDE.md. - Why: Leo's PR #15 review required these two changes before merge. - Details: Broken links were references to claims that don't yet exist (demand signals). Brackets removed so they read as plain text rather than broken links. Co-Authored-By: Claude Opus 4.6 <noreply@anthropic.com>
28 lines
3.3 KiB
Markdown
28 lines
3.3 KiB
Markdown
---
|
|
description: Current gene therapies cost 2-4 million dollars per treatment using ex vivo editing but in vivo approaches like Verve's one-time PCSK9 base editing infusion showing 53 percent LDL reduction could reach 50-200K by 2035 making curative medicine scalable
|
|
type: claim
|
|
domain: health
|
|
created: 2026-02-17
|
|
source: "IGI CRISPR clinical trials update 2025; BioPharma Dive Verve PCSK9 data; BioInformant FDA-approved CGT database; GEN reimbursement outlook 2025; PMC gene therapy pipeline analysis"
|
|
confidence: likely
|
|
---
|
|
|
|
# gene editing is shifting from ex vivo to in vivo delivery via lipid nanoparticles which will reduce curative therapy costs from millions to hundreds of thousands per treatment
|
|
|
|
As of early 2026, 46 cell and gene therapies have FDA approval, with prices concentrated in the $2-4M range: Casgevy ($2.2M for sickle cell), Lyfgenia ($3.1M), Zolgensma ($2.1M for SMA), Hemgenix ($3.5M for hemophilia B). These are all ex vivo therapies -- harvest cells, edit them, reinfuse -- requiring complex per-patient manufacturing that drives costs.
|
|
|
|
The shift to in vivo delivery changes the economics entirely. Verve Therapeutics' VERVE-102 demonstrated the paradigm: a one-time IV infusion of lipid nanoparticle-delivered base editors targeting PCSK9 in the liver reduced LDL cholesterol by 53% and PCSK9 protein by 60% at the highest dose. If validated at scale, a single infusion could replace decades of statin therapy. Eli Lilly is collaborating on Phase 2 trials. Beyond cardiovascular disease, base editing showed >60% fetal hemoglobin induction in 7 sickle cell patients (Beam Therapeutics), and the first prime editing clinical trial was cleared for chronic granulomatous disease (Prime Medicine, May 2024).
|
|
|
|
The technology progression runs from CRISPR-Cas9 (double-strand breaks) to base editing (single letter changes without breaks) to prime editing (precise insertions, deletions, all 12 point mutations without breaks). Each generation increases precision and reduces off-target risk. The pipeline contains 2,500+ active CGT INDs and ~1,300 gene therapy INDs.
|
|
|
|
LNP-based in vivo therapies could reach the $50-200K range by 2032-2035, making them cost-competitive with lifetime chronic disease management. Diseases already functionally cured include sickle cell, beta thalassemia, SMA, hemophilia A and B, and Wiskott-Aldrich syndrome. By 2035, familial hypercholesterolemia, hereditary angioedema, glycogen storage disease, and select inherited retinal dystrophies will likely join the list.
|
|
|
|
---
|
|
|
|
Relevant Notes:
|
|
- [[the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline]] -- gene therapy front-loading creates enormous single-year expenditures even as it eliminates lifetime chronic costs
|
|
- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] -- gene editing's one-time cure model is the structural opposite of GLP-1's chronic use model
|
|
- [[AI compresses drug discovery timelines by 30-40 percent but has not yet improved the 90 percent clinical failure rate that determines industry economics]] -- AI accelerates target identification but gene editing provides the delivery mechanism for curative interventions
|
|
|
|
Topics:
|
|
- health and wellness
|